Novartis is expected to present the latest results in October from its ongoing Str1ve study, which is monitoring the effects of its gene therapy AVXS-101 on 15 infants with spinal muscular atrophy. Rivals Biogen and Chop-Intend will be anxious to know if Novartis has built on its last set of impressive results in April, which saw six infants' motor function increase by an average of 7.8 points on the so-called Roche scale, one month after treatment, while no "events" – deaths or a need for near-permanent breathing support – were recorded.
Novartis is expected to present the latest results in October from its ongoing Str1ve study, which is monitoring the effects of its gene therapy AVXS-101 on 15 infants with spinal muscular atrophy. Rivals Biogen and Roche will be anxious to know if Novartis has built on its last set of impressive results in April, which saw six infants' motor function increase by an average of 7.8 points on the so-called Chop-Intend scale, one month after treatment, while no "events" – deaths or a need for near-permanent breathing support – were recorded.